gyki 52466 has been researched along with Epilepsy in 16 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to determine whether the anticonvulsant effect of 2, 3-benzodiazepines is also displayed in a model of in vitro epilepsy, such as the "epileptiform" hippocampal slice, we studied the effects of 2,3-benzodiazepine 1-(4-aminophenyl)-4-methyl-7, 8-methylenedioxe-5H 2,3-benzodiazepine hydrochloride (GYKI 52466) and some new 2,3-benzodiazepine derivatives on CA1 basal neuronal excitability and on CA1 epileptiform burst activity produced by 4-aminopyridine in rat hippocampal slices." | 3.70 | Effects of GYKI 52466 and some 2,3-benzodiazepine derivatives on hippocampal in vitro basal neuronal excitability and 4-aminopyridine epileptic activity. ( Gatta, F; Marinelli, S; Sagratella, S, 2000) |
| "Two potent glutamate antagonists, NBQX and GYKI 52466, that act selectively on non-NMDA receptors, have been tested for anticonvulsant activity in 3 models of reflex epilepsy (sound-induced seizures in DBA/2 mice and in genetically epilepsy-prone rats and photically-induced myoclonus in Papio papio) and in amygdala kindled rats." | 3.68 | The effects of AMPA receptor antagonists on kindled seizures and on reflex epilepsy in rodents and primates. ( Chapman, AG; Craggs, MD; Dürmüller, N; Meldrum, BS; Smith, SE, 1992) |
| " injections at 1-h intervals, the first dosage was given shortly after the intrastriatal injection of (S)-alpha-amino-3-hydroxy-5,7-methylisoxazole-4-propionic acid (AMPA) (2." | 1.31 | Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. ( Banczerowski-Pelyhe, I; Gulyás-Kovács, A; Takács, J; Tarnawa, I; Világi, I, 2002) |
| "There was a commensurate reduction in seizure-related neuronal loss in the limbic regions of the brain." | 1.31 | In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466. ( Lees, GJ; Leong, W, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gitto, R | 3 |
| Orlando, V | 1 |
| Quartarone, S | 1 |
| De Sarro, G | 3 |
| De Sarro, A | 3 |
| Russo, E | 1 |
| Ferreri, G | 1 |
| Chimirri, A | 3 |
| Kim, JE | 2 |
| Park, H | 2 |
| Lee, JE | 1 |
| Kim, TH | 1 |
| Kang, TC | 2 |
| Lee, DS | 1 |
| Gulyás-Kovács, A | 2 |
| Dóczi, J | 1 |
| Tarnawa, I | 3 |
| Détári, L | 1 |
| Banczerowski-Pelyhe, I | 2 |
| Világi, I | 4 |
| Takács, J | 1 |
| Kubová, H | 1 |
| Mikulecká, A | 1 |
| Mares, P | 1 |
| Rizzo, M | 2 |
| Sinopoli, VA | 1 |
| Zappala, M | 2 |
| Spagnolo, C | 1 |
| Scotto, G | 1 |
| Barna, B | 2 |
| Szente, M | 2 |
| Szász, A | 2 |
| Marinelli, S | 1 |
| Gatta, F | 1 |
| Sagratella, S | 1 |
| Szabados, T | 1 |
| Gigler, G | 1 |
| Gyertyán, I | 1 |
| Gacsályi, I | 1 |
| Lévay, G | 1 |
| Kapus, G | 1 |
| Székely, JI | 1 |
| Durand, J | 1 |
| Ruiz, A | 1 |
| Lees, GJ | 1 |
| Leong, W | 1 |
| Meldrum, BS | 2 |
| Craggs, MD | 1 |
| Dürmüller, N | 2 |
| Smith, SE | 2 |
| Chapman, AG | 1 |
16 other studies available for gyki 52466 and Epilepsy
| Article | Year |
|---|---|
Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Benzodiazepines; | 2003 |
PTEN Is Required for The Anti-Epileptic Effects of AMPA Receptor Antagonists in Chronic Epileptic Rats.
Topics: Animals; Benzodiazepines; Chronic Disease; Down-Regulation; Epilepsy; Hippocampus; Male; Models, Bio | 2020 |
Src/CK2/PTEN-Mediated GluN2B and CREB Dephosphorylations Regulate the Responsiveness to AMPA Receptor Antagonists in Chronic Epilepsy Rats.
Topics: Animals; Benzodiazepines; Casein Kinase II; Cyclic AMP Response Element-Binding Protein; Epilepsy; E | 2020 |
Comparison of spontaneous and evoked epileptiform activity in three in vitro epilepsy models.
Topics: 2-Amino-5-phosphonovalerate; 4-Aminopyridine; Animals; Anti-Anxiety Agents; Benzodiazepines; Bicucul | 2002 |
Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Anti-Anxiety Ag | 2002 |
Non-NMDA receptor antagonist GYKI 52466 suppresses cortical afterdischarges in immature rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Cerebral Cortex; Electric Stimulation; Electrodes, Im | 1997 |
Relationship between anticonvulsant activity and plasma level of some 2,3-benzodiazepines in genetically epilepsy-prone rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Epilepsy; Motor Activity; Motor Skil | 1998 |
Anticonvulsant activity and plasma level of 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy-prone rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Epilepsy; Male; Motor Activity; Post | 1999 |
The anticonvulsive effect of non-NMDA antagonist GYKI 52466 on 3-aminopyridine-induced primary and secondary cortical ictal activity in rat.
Topics: Aminopyridines; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cerebral Cortex; Epi | 1999 |
Anticonvulsive effect of AMPA receptor antagonist GYKI 52466 on 4-aminopyridine-induced cortical ictal activity in rat.
Topics: 4-Aminopyridine; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cerebral Cortex; El | 2000 |
Effects of GYKI 52466 and some 2,3-benzodiazepine derivatives on hippocampal in vitro basal neuronal excitability and 4-aminopyridine epileptic activity.
Topics: 4-Aminopyridine; Animals; Anti-Anxiety Agents; Anticonvulsants; Axons; Benzodiazepines; Calcium Chan | 2000 |
Duration of action of GYKI 52466 and its analogues in antiepileptic, anti-ischaemic and muscle relaxant tests.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Brain Ischemia; Epilepsy; Excitatory Amino Acid Antag | 1999 |
AMPA receptor antagonists, GYKI 52466 and NBQX, do not block the induction of long-term potentiation at therapeutically relevant concentrations.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Dose-Response Relationship, Drug; Epilepsy; Excitator | 2000 |
In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 2001 |
The effects of AMPA receptor antagonists on kindled seizures and on reflex epilepsy in rodents and primates.
Topics: Acoustic Stimulation; Amygdala; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cere | 1992 |
The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Behavior, Animal; Benzodiazepin | 1991 |